Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
7. BRIC: Will slowdown in China mean dwindling returns for device makers?
China economic growth slows to rates not seen in more than 3 years, an ominous sign for the clutch of med-tech titans with aggressive strategies in the country.
6. Med-Tech CEOs turn passion into mission with boot camp for vets
Abiomed CEO Michael Minogue, along with AdvaMed and other medical device company CEOs launch the MedTech Veteran Program for Returning Heroes, a boot camp for military veterans and wounded warriors.
5. Intuitive Surgical’s da Vinci surgical bot back online in Denmark
Hospitals in Denmark resume da Vinci robot-assisted surgeries after a 2-week hiatus spurred by 1 center’s sterilization concerns.
4. Joint down, spine up: Trends in orthopedics
Group purchasing organization Novation reports on recent trends in orthopedic products, finding upward momentum in spinal devices but slowing growth in U.S. joint markets.
3. FDA warns on Covidien’s liquid embolic system following 9 patient deaths
The FDA warns that the Onyx liquid embolic system made by Covidien subsidiary ev3 may be linked to 9 patient deaths due to delivery catheters that became stuck in patients’ brains.
2. Med-tech trends: The most talked about medical device companies in June 2012
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
1. BSX’s incoming CEO Mahoney on leaving J&J: “The opportunity was too good to pass up”
Incoming CEO Mike Mahoney tells an audience at MassDevice’s Big 100 Roundtable East event about the difficult decision to leave a promising career at Johnson & Johnson to – eventually – take the reins at Boston Scientific.
